Skip to content

Treatment of Post-Stroke Central Pain

Efficacy and Safety of Short-Term Spinal Cord Stimulation Combined With Pharmacotherapy for Central Post-Stroke Pain: A Single-Center, Randomized, Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07593313
Enrollment
80
Registered
2026-05-18
Start date
2024-01-01
Completion date
2026-08-01
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Post-Stroke Pain

Brief summary

To evaluate the short-term analgesic efficacy of stSCS combined with pharmacotherapy compared with pharmacotherapy alone in patients with CPSP, measured by Numerical Rating Scale (NRS) score immediately after treatment.

Interventions

PROCEDUREstSCS+Gabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

Patients received stSCS in addition to conventional pharmacotherapy. stSCS Procedure: Under digital subtraction angiography (DSA) guidance, a temporary electrode (typically an 8-contact electrode) was percutaneously placed into the corresponding spinal cord segment (cervical C2-C4 or thoracic T8-T10, depending on the pain distribution area). The electrode was connected to an external stimulator to deliver continuous stimulation for 7-14 days. Stimulation parameters were as follows: frequency 40-60 Hz (conventional mode) or BurstDR mode, pulse width 210-450 μs, and amplitude individually adjusted based on the patient's sensory threshold (targeting a comfortable paresthesia covering the painful area). After the test period, the electrode was removed without a second-stage implantation. Postoperatively, patients continued receiving baseline pharmacotherapy, which could be reduced as appropriate.

DRUGGabapentin or Pregabalin (with optional Duloxetine or Amitriptyline)

Patients received conventional pharmacotherapy alone without any form of SCS. The medication regimen followed the 2025 International Association for the Study of Pain (IASP) recommendations, with gabapentin (starting at 300 mg/d, gradually titrated to 900-1800 mg/d based on tolerability, administered in 2-3 divided doses) or pregabalin (starting at 75 mg/d, gradually titrated to 150-300 mg/d in 2-3 divided doses) as the foundation, and could be combined with duloxetine (60-120 mg/d) or amitriptyline (25-75 mg at bedtime). Drug doses were individually adjusted by the attending physician according to patient response and tolerability.

Sponsors

Nanchong Central Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of central post-stroke pain (CPSP) according to the International Association for the Study of Pain (IASP) criteria * Clear history of stroke confirmed by cranial CT or MRI * Pain occurring after stroke and distributed in body parts corresponding to central nervous system injury * Pain with neuropathic characteristics (e.g., burning sensation, electric shock sensation, needle prick sensation) * Pain not explained by other causes * Age ≥ 18 years * Pain duration ≥ 3 months * Baseline pain Numerical Rating Scale (NRS) score ≥ 4 points * Complete clinical data with follow-up time ≥ 6 months

Exclusion criteria

* History of chronic pain before stroke * Severe cognitive impairment that prevents cooperation with pain assessment (Mini-Mental State Examination, MMSE \< 15 points) * Contraindications to spinal cord stimulation (SCS), such as coagulation disorders, active infections, or mental diseases that prevent cooperation * Malignant tumors or other severe organic diseases with expected survival \< 1 year

Design outcomes

Primary

MeasureTime frameDescription
Numerical Rating Scale (NRS) scoreSix monthsThe primary outcome was pain intensity measured by the NRS(0-10) recorded at baseline, immediately after stimulation termination (study group)/at the corresponding time point after treatment (control group), and at 1, 3, and 6 months post-treatment. The proportions of patients with an NRS reduction of ≥30% and ≥50% from baseline were also recorded, with the latter defined as treatment response. NRS ranges from 0 (no pain) to 10 (worst possible pain). Higher scores indicate worse pain.

Secondary

MeasureTime frameDescription
Change in Sleep Quality assessed by the Pittsburgh Sleep Quality Index (PSQI)6 monthsThe PSQI total score ranges from 0 to 21. Higher scores indicate worse sleep quality
Change in Physical Health assessed by the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS)6 monthsThe SF-36 PCS score ranges from 0 to 100. Higher scores indicate better physical health
Change in Mental Health assessed by the 36-Item Short Form Health Survey Mental Component Summary (SF-36 MCS)6 monthsThe SF-36 MCS score ranges from 0 to 100. Higher scores indicate better mental health

Countries

China

Contacts

CONTACTZhenguo Gao
gaozhenguo0822@163.com18404999336

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026